nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP2C9—brain cancer	0.475	1	CbGaD
Thalidomide—CYP1A2—Carmustine—brain cancer	0.0494	0.273	CbGbCtD
Thalidomide—PTGS2—Etoposide—brain cancer	0.0388	0.215	CbGbCtD
Thalidomide—PTGS1—Etoposide—brain cancer	0.0328	0.181	CbGbCtD
Thalidomide—CYP2E1—Etoposide—brain cancer	0.0253	0.14	CbGbCtD
Thalidomide—CYP3A5—Etoposide—brain cancer	0.0197	0.109	CbGbCtD
Thalidomide—CYP1A2—Etoposide—brain cancer	0.0146	0.0811	CbGbCtD
Thalidomide—FGFR2—skull—brain cancer	0.00562	0.127	CbGeAlD
Thalidomide—FGFR2—hindbrain—brain cancer	0.00222	0.0503	CbGeAlD
Thalidomide—NFKB1—telencephalon—brain cancer	0.0015	0.034	CbGeAlD
Thalidomide—FGFR2—brainstem—brain cancer	0.00127	0.0288	CbGeAlD
Thalidomide—CRBN—telencephalon—brain cancer	0.00126	0.0285	CbGeAlD
Thalidomide—NFKB1—gonad—brain cancer	0.00125	0.0284	CbGeAlD
Thalidomide—NFKB1—pituitary gland—brain cancer	0.00122	0.0277	CbGeAlD
Thalidomide—FGFR2—telencephalon—brain cancer	0.00113	0.0256	CbGeAlD
Thalidomide—CRBN—gonad—brain cancer	0.00105	0.0238	CbGeAlD
Thalidomide—CRBN—pituitary gland—brain cancer	0.00103	0.0232	CbGeAlD
Thalidomide—CRBN—medulla oblongata—brain cancer	0.00099	0.0224	CbGeAlD
Thalidomide—NFKB1—endocrine gland—brain cancer	0.000948	0.0215	CbGeAlD
Thalidomide—NFKB1—head—brain cancer	0.000936	0.0212	CbGeAlD
Thalidomide—PTGS1—ganglion—brain cancer	0.00093	0.0211	CbGeAlD
Thalidomide—CRBN—midbrain—brain cancer	0.000904	0.0205	CbGeAlD
Thalidomide—CRBN—spinal cord—brain cancer	0.000882	0.02	CbGeAlD
Thalidomide—NFKB1—central nervous system—brain cancer	0.000854	0.0194	CbGeAlD
Thalidomide—NFKB1—cerebellum—brain cancer	0.000835	0.0189	CbGeAlD
Thalidomide—PTGS1—endothelium—brain cancer	0.000802	0.0182	CbGeAlD
Thalidomide—CRBN—endocrine gland—brain cancer	0.000794	0.018	CbGeAlD
Thalidomide—FGFR2—spinal cord—brain cancer	0.000791	0.0179	CbGeAlD
Thalidomide—CRBN—head—brain cancer	0.000784	0.0178	CbGeAlD
Thalidomide—PTGS2—endothelium—brain cancer	0.000767	0.0174	CbGeAlD
Thalidomide—PTGS1—blood vessel—brain cancer	0.00074	0.0168	CbGeAlD
Thalidomide—CRBN—central nervous system—brain cancer	0.000716	0.0162	CbGeAlD
Thalidomide—FGFR2—endocrine gland—brain cancer	0.000712	0.0161	CbGeAlD
Thalidomide—PTGS2—blood vessel—brain cancer	0.000707	0.016	CbGeAlD
Thalidomide—FGFR2—head—brain cancer	0.000703	0.0159	CbGeAlD
Thalidomide—CRBN—cerebellum—brain cancer	0.0007	0.0159	CbGeAlD
Thalidomide—NFKB1—brain—brain cancer	0.000678	0.0154	CbGeAlD
Thalidomide—FGFR2—central nervous system—brain cancer	0.000641	0.0145	CbGeAlD
Thalidomide—FGFR2—cerebellum—brain cancer	0.000627	0.0142	CbGeAlD
Thalidomide—CRBN—brain—brain cancer	0.000568	0.0129	CbGeAlD
Thalidomide—FGFR2—brain—brain cancer	0.000509	0.0115	CbGeAlD
Thalidomide—CYP2E1—telencephalon—brain cancer	0.000372	0.00844	CbGeAlD
Thalidomide—PTGS1—telencephalon—brain cancer	0.000359	0.00813	CbGeAlD
Thalidomide—PTGS2—telencephalon—brain cancer	0.000343	0.00777	CbGeAlD
Thalidomide—CYP2C19—endocrine gland—brain cancer	0.00032	0.00725	CbGeAlD
Thalidomide—CYP2E1—medulla oblongata—brain cancer	0.000293	0.00663	CbGeAlD
Thalidomide—PTGS1—pituitary gland—brain cancer	0.000292	0.00662	CbGeAlD
Thalidomide—PTGS2—pituitary gland—brain cancer	0.000279	0.00633	CbGeAlD
Thalidomide—PTGS2—medulla oblongata—brain cancer	0.000269	0.00611	CbGeAlD
Thalidomide—CYP1A2—endocrine gland—brain cancer	0.000261	0.00592	CbGeAlD
Thalidomide—CYP2E1—spinal cord—brain cancer	0.000261	0.00591	CbGeAlD
Thalidomide—CYP1A1—endocrine gland—brain cancer	0.000258	0.00584	CbGeAlD
Thalidomide—CYP1A1—head—brain cancer	0.000254	0.00576	CbGeAlD
Thalidomide—CYP3A5—endocrine gland—brain cancer	0.000252	0.00571	CbGeAlD
Thalidomide—PTGS1—spinal cord—brain cancer	0.000251	0.0057	CbGeAlD
Thalidomide—CYP2C9—endocrine gland—brain cancer	0.000248	0.00562	CbGeAlD
Thalidomide—PTGS2—midbrain—brain cancer	0.000246	0.00558	CbGeAlD
Thalidomide—PTGS2—spinal cord—brain cancer	0.00024	0.00544	CbGeAlD
Thalidomide—CYP2E1—endocrine gland—brain cancer	0.000235	0.00532	CbGeAlD
Thalidomide—CYP1A1—central nervous system—brain cancer	0.000232	0.00526	CbGeAlD
Thalidomide—CYP2E1—head—brain cancer	0.000232	0.00526	CbGeAlD
Thalidomide—PTGS1—endocrine gland—brain cancer	0.000226	0.00513	CbGeAlD
Thalidomide—PTGS1—head—brain cancer	0.000223	0.00506	CbGeAlD
Thalidomide—PTGS2—endocrine gland—brain cancer	0.000216	0.0049	CbGeAlD
Thalidomide—PTGS2—head—brain cancer	0.000214	0.00484	CbGeAlD
Thalidomide—CYP2E1—central nervous system—brain cancer	0.000212	0.0048	CbGeAlD
Thalidomide—CYP2E1—cerebellum—brain cancer	0.000207	0.00469	CbGeAlD
Thalidomide—PTGS1—central nervous system—brain cancer	0.000204	0.00462	CbGeAlD
Thalidomide—PTGS2—central nervous system—brain cancer	0.000195	0.00442	CbGeAlD
Thalidomide—Insomnia—Procarbazine—brain cancer	0.000192	0.00108	CcSEcCtD
Thalidomide—PTGS2—cerebellum—brain cancer	0.000191	0.00432	CbGeAlD
Thalidomide—Paraesthesia—Procarbazine—brain cancer	0.00019	0.00107	CcSEcCtD
Thalidomide—Sinusitis—Temozolomide—brain cancer	0.000189	0.00106	CcSEcCtD
Thalidomide—Somnolence—Procarbazine—brain cancer	0.000188	0.00106	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000188	0.00106	CcSEcCtD
Thalidomide—Cramp muscle—Etoposide—brain cancer	0.000188	0.00106	CcSEcCtD
Thalidomide—Ill-defined disorder—Hydroxyurea—brain cancer	0.000187	0.00105	CcSEcCtD
Thalidomide—Anaemia—Hydroxyurea—brain cancer	0.000186	0.00105	CcSEcCtD
Thalidomide—Hypoaesthesia—Carmustine—brain cancer	0.000186	0.00105	CcSEcCtD
Thalidomide—Decreased appetite—Procarbazine—brain cancer	0.000184	0.00104	CcSEcCtD
Thalidomide—CYP1A1—brain—brain cancer	0.000184	0.00418	CbGeAlD
Thalidomide—Alanine aminotransferase increased—Etoposide—brain cancer	0.000184	0.00104	CcSEcCtD
Thalidomide—Oedema peripheral—Carmustine—brain cancer	0.000184	0.00103	CcSEcCtD
Thalidomide—Fatigue—Procarbazine—brain cancer	0.000183	0.00103	CcSEcCtD
Thalidomide—Malaise—Hydroxyurea—brain cancer	0.000181	0.00102	CcSEcCtD
Thalidomide—Constipation—Procarbazine—brain cancer	0.000181	0.00102	CcSEcCtD
Thalidomide—Pain—Procarbazine—brain cancer	0.000181	0.00102	CcSEcCtD
Thalidomide—Hepatitis—Temozolomide—brain cancer	0.00018	0.00102	CcSEcCtD
Thalidomide—Dysphagia—Etoposide—brain cancer	0.00018	0.00101	CcSEcCtD
Thalidomide—Leukopenia—Hydroxyurea—brain cancer	0.00018	0.00101	CcSEcCtD
Thalidomide—Visual impairment—Carmustine—brain cancer	0.00018	0.00101	CcSEcCtD
Thalidomide—Hypoaesthesia—Temozolomide—brain cancer	0.00018	0.00101	CcSEcCtD
Thalidomide—Pharyngitis—Temozolomide—brain cancer	0.000179	0.00101	CcSEcCtD
Thalidomide—Urinary tract disorder—Temozolomide—brain cancer	0.000178	0.001	CcSEcCtD
Thalidomide—Oedema peripheral—Temozolomide—brain cancer	0.000178	0.001	CcSEcCtD
Thalidomide—Bronchospasm—Etoposide—brain cancer	0.000177	0.000998	CcSEcCtD
Thalidomide—Urethral disorder—Temozolomide—brain cancer	0.000177	0.000995	CcSEcCtD
Thalidomide—Feeling abnormal—Procarbazine—brain cancer	0.000175	0.000983	CcSEcCtD
Thalidomide—Eye disorder—Carmustine—brain cancer	0.000174	0.000982	CcSEcCtD
Thalidomide—Convulsion—Hydroxyurea—brain cancer	0.000174	0.00098	CcSEcCtD
Thalidomide—Visual impairment—Temozolomide—brain cancer	0.000174	0.000978	CcSEcCtD
Thalidomide—Gastrointestinal pain—Procarbazine—brain cancer	0.000173	0.000975	CcSEcCtD
Thalidomide—Pancytopenia—Etoposide—brain cancer	0.000171	0.000964	CcSEcCtD
Thalidomide—Erythema multiforme—Temozolomide—brain cancer	0.000171	0.00096	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00017	0.000956	CcSEcCtD
Thalidomide—Discomfort—Hydroxyurea—brain cancer	0.000169	0.000952	CcSEcCtD
Thalidomide—Neutropenia—Etoposide—brain cancer	0.000169	0.000949	CcSEcCtD
Thalidomide—Eye disorder—Temozolomide—brain cancer	0.000169	0.000949	CcSEcCtD
Thalidomide—Urticaria—Procarbazine—brain cancer	0.000168	0.000948	CcSEcCtD
Thalidomide—Tinnitus—Temozolomide—brain cancer	0.000168	0.000947	CcSEcCtD
Thalidomide—CYP2E1—brain—brain cancer	0.000168	0.00381	CbGeAlD
Thalidomide—Abdominal pain—Procarbazine—brain cancer	0.000168	0.000943	CcSEcCtD
Thalidomide—Body temperature increased—Procarbazine—brain cancer	0.000168	0.000943	CcSEcCtD
Thalidomide—Cardiac disorder—Temozolomide—brain cancer	0.000167	0.000942	CcSEcCtD
Thalidomide—Arrhythmia—Carmustine—brain cancer	0.000167	0.000938	CcSEcCtD
Thalidomide—Alopecia—Carmustine—brain cancer	0.000165	0.000928	CcSEcCtD
Thalidomide—Oedema—Hydroxyurea—brain cancer	0.000164	0.000923	CcSEcCtD
Thalidomide—Angiopathy—Temozolomide—brain cancer	0.000164	0.000921	CcSEcCtD
Thalidomide—Mental disorder—Carmustine—brain cancer	0.000164	0.00092	CcSEcCtD
Thalidomide—Infection—Hydroxyurea—brain cancer	0.000163	0.000917	CcSEcCtD
Thalidomide—Immune system disorder—Temozolomide—brain cancer	0.000163	0.000917	CcSEcCtD
Thalidomide—Mediastinal disorder—Temozolomide—brain cancer	0.000163	0.000915	CcSEcCtD
Thalidomide—Malnutrition—Carmustine—brain cancer	0.000163	0.000914	CcSEcCtD
Thalidomide—PTGS1—brain—brain cancer	0.000162	0.00367	CbGeAlD
Thalidomide—Chills—Temozolomide—brain cancer	0.000162	0.000911	CcSEcCtD
Thalidomide—Pneumonia—Etoposide—brain cancer	0.000162	0.00091	CcSEcCtD
Thalidomide—Nervous system disorder—Hydroxyurea—brain cancer	0.000161	0.000905	CcSEcCtD
Thalidomide—Infestation—Etoposide—brain cancer	0.000161	0.000905	CcSEcCtD
Thalidomide—Infestation NOS—Etoposide—brain cancer	0.000161	0.000905	CcSEcCtD
Thalidomide—Thrombocytopenia—Hydroxyurea—brain cancer	0.000161	0.000904	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000159	0.000897	CcSEcCtD
Thalidomide—Alopecia—Temozolomide—brain cancer	0.000159	0.000897	CcSEcCtD
Thalidomide—Skin disorder—Hydroxyurea—brain cancer	0.000159	0.000897	CcSEcCtD
Thalidomide—Acute coronary syndrome—Etoposide—brain cancer	0.000159	0.000892	CcSEcCtD
Thalidomide—Renal failure—Etoposide—brain cancer	0.000158	0.00089	CcSEcCtD
Thalidomide—Mental disorder—Temozolomide—brain cancer	0.000158	0.000889	CcSEcCtD
Thalidomide—Myocardial infarction—Etoposide—brain cancer	0.000158	0.000887	CcSEcCtD
Thalidomide—Neuropathy peripheral—Etoposide—brain cancer	0.000158	0.000887	CcSEcCtD
Thalidomide—Back pain—Carmustine—brain cancer	0.000157	0.000885	CcSEcCtD
Thalidomide—Malnutrition—Temozolomide—brain cancer	0.000157	0.000884	CcSEcCtD
Thalidomide—Stomatitis—Etoposide—brain cancer	0.000157	0.000882	CcSEcCtD
Thalidomide—Anorexia—Hydroxyurea—brain cancer	0.000156	0.00088	CcSEcCtD
Thalidomide—Hypersensitivity—Procarbazine—brain cancer	0.000156	0.000879	CcSEcCtD
Thalidomide—PTGS2—brain—brain cancer	0.000155	0.00351	CbGeAlD
Thalidomide—Dysgeusia—Temozolomide—brain cancer	0.000154	0.000865	CcSEcCtD
Thalidomide—Vision blurred—Carmustine—brain cancer	0.000153	0.000862	CcSEcCtD
Thalidomide—Tremor—Carmustine—brain cancer	0.000152	0.000857	CcSEcCtD
Thalidomide—Asthenia—Procarbazine—brain cancer	0.000152	0.000856	CcSEcCtD
Thalidomide—Back pain—Temozolomide—brain cancer	0.000152	0.000855	CcSEcCtD
Thalidomide—Anaemia—Carmustine—brain cancer	0.00015	0.000845	CcSEcCtD
Thalidomide—Agranulocytosis—Etoposide—brain cancer	0.00015	0.000844	CcSEcCtD
Thalidomide—Pruritus—Procarbazine—brain cancer	0.00015	0.000844	CcSEcCtD
Thalidomide—Agitation—Carmustine—brain cancer	0.000149	0.00084	CcSEcCtD
Thalidomide—Vision blurred—Temozolomide—brain cancer	0.000148	0.000833	CcSEcCtD
Thalidomide—Tremor—Temozolomide—brain cancer	0.000147	0.000828	CcSEcCtD
Thalidomide—Dyspnoea—Hydroxyurea—brain cancer	0.000146	0.000823	CcSEcCtD
Thalidomide—Somnolence—Hydroxyurea—brain cancer	0.000146	0.000821	CcSEcCtD
Thalidomide—Ill-defined disorder—Temozolomide—brain cancer	0.000146	0.00082	CcSEcCtD
Thalidomide—Leukopenia—Carmustine—brain cancer	0.000145	0.000819	CcSEcCtD
Thalidomide—Anaemia—Temozolomide—brain cancer	0.000145	0.000817	CcSEcCtD
Thalidomide—Diarrhoea—Procarbazine—brain cancer	0.000145	0.000816	CcSEcCtD
Thalidomide—Dyspepsia—Hydroxyurea—brain cancer	0.000144	0.000813	CcSEcCtD
Thalidomide—Agitation—Temozolomide—brain cancer	0.000144	0.000812	CcSEcCtD
Thalidomide—Hypoaesthesia—Etoposide—brain cancer	0.000144	0.000808	CcSEcCtD
Thalidomide—Angioedema—Temozolomide—brain cancer	0.000144	0.000807	CcSEcCtD
Thalidomide—Decreased appetite—Hydroxyurea—brain cancer	0.000143	0.000803	CcSEcCtD
Thalidomide—Urinary tract disorder—Etoposide—brain cancer	0.000143	0.000802	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000142	0.000797	CcSEcCtD
Thalidomide—Malaise—Temozolomide—brain cancer	0.000142	0.000797	CcSEcCtD
Thalidomide—Urethral disorder—Etoposide—brain cancer	0.000142	0.000796	CcSEcCtD
Thalidomide—Fatigue—Hydroxyurea—brain cancer	0.000141	0.000796	CcSEcCtD
Thalidomide—Vertigo—Temozolomide—brain cancer	0.000141	0.000794	CcSEcCtD
Thalidomide—Convulsion—Carmustine—brain cancer	0.000141	0.000792	CcSEcCtD
Thalidomide—Leukopenia—Temozolomide—brain cancer	0.000141	0.000791	CcSEcCtD
Thalidomide—Hypertension—Carmustine—brain cancer	0.00014	0.00079	CcSEcCtD
Thalidomide—Constipation—Hydroxyurea—brain cancer	0.00014	0.000789	CcSEcCtD
Thalidomide—Pain—Hydroxyurea—brain cancer	0.00014	0.000789	CcSEcCtD
Thalidomide—Dizziness—Procarbazine—brain cancer	0.00014	0.000789	CcSEcCtD
Thalidomide—Palpitations—Temozolomide—brain cancer	0.000139	0.000781	CcSEcCtD
Thalidomide—Chest pain—Carmustine—brain cancer	0.000138	0.000779	CcSEcCtD
Thalidomide—Myalgia—Carmustine—brain cancer	0.000138	0.000779	CcSEcCtD
Thalidomide—Anxiety—Carmustine—brain cancer	0.000138	0.000776	CcSEcCtD
Thalidomide—Cough—Temozolomide—brain cancer	0.000137	0.000771	CcSEcCtD
Thalidomide—Erythema multiforme—Etoposide—brain cancer	0.000136	0.000768	CcSEcCtD
Thalidomide—Convulsion—Temozolomide—brain cancer	0.000136	0.000766	CcSEcCtD
Thalidomide—Hypertension—Temozolomide—brain cancer	0.000136	0.000763	CcSEcCtD
Thalidomide—Feeling abnormal—Hydroxyurea—brain cancer	0.000135	0.000761	CcSEcCtD
Thalidomide—Eye disorder—Etoposide—brain cancer	0.000135	0.000759	CcSEcCtD
Thalidomide—Vomiting—Procarbazine—brain cancer	0.000135	0.000758	CcSEcCtD
Thalidomide—Cardiac disorder—Etoposide—brain cancer	0.000134	0.000754	CcSEcCtD
Thalidomide—Confusional state—Carmustine—brain cancer	0.000134	0.000753	CcSEcCtD
Thalidomide—Myalgia—Temozolomide—brain cancer	0.000134	0.000752	CcSEcCtD
Thalidomide—Arthralgia—Temozolomide—brain cancer	0.000134	0.000752	CcSEcCtD
Thalidomide—Rash—Procarbazine—brain cancer	0.000134	0.000752	CcSEcCtD
Thalidomide—Dermatitis—Procarbazine—brain cancer	0.000134	0.000751	CcSEcCtD
Thalidomide—Anxiety—Temozolomide—brain cancer	0.000133	0.00075	CcSEcCtD
Thalidomide—Headache—Procarbazine—brain cancer	0.000133	0.000747	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000133	0.000747	CcSEcCtD
Thalidomide—Oedema—Carmustine—brain cancer	0.000133	0.000746	CcSEcCtD
Thalidomide—Discomfort—Temozolomide—brain cancer	0.000132	0.000743	CcSEcCtD
Thalidomide—Infection—Carmustine—brain cancer	0.000132	0.000741	CcSEcCtD
Thalidomide—Angiopathy—Etoposide—brain cancer	0.000131	0.000737	CcSEcCtD
Thalidomide—Dry mouth—Temozolomide—brain cancer	0.000131	0.000736	CcSEcCtD
Thalidomide—Immune system disorder—Etoposide—brain cancer	0.00013	0.000734	CcSEcCtD
Thalidomide—Mediastinal disorder—Etoposide—brain cancer	0.00013	0.000732	CcSEcCtD
Thalidomide—Thrombocytopenia—Carmustine—brain cancer	0.00013	0.000731	CcSEcCtD
Thalidomide—Body temperature increased—Hydroxyurea—brain cancer	0.00013	0.00073	CcSEcCtD
Thalidomide—Chills—Etoposide—brain cancer	0.00013	0.000729	CcSEcCtD
Thalidomide—Tachycardia—Carmustine—brain cancer	0.000129	0.000728	CcSEcCtD
Thalidomide—Confusional state—Temozolomide—brain cancer	0.000129	0.000727	CcSEcCtD
Thalidomide—Oedema—Temozolomide—brain cancer	0.000128	0.000721	CcSEcCtD
Thalidomide—Alopecia—Etoposide—brain cancer	0.000128	0.000718	CcSEcCtD
Thalidomide—Infection—Temozolomide—brain cancer	0.000127	0.000717	CcSEcCtD
Thalidomide—Anorexia—Carmustine—brain cancer	0.000126	0.000711	CcSEcCtD
Thalidomide—Nausea—Procarbazine—brain cancer	0.000126	0.000709	CcSEcCtD
Thalidomide—Nervous system disorder—Temozolomide—brain cancer	0.000126	0.000707	CcSEcCtD
Thalidomide—Thrombocytopenia—Temozolomide—brain cancer	0.000125	0.000706	CcSEcCtD
Thalidomide—Skin disorder—Temozolomide—brain cancer	0.000124	0.000701	CcSEcCtD
Thalidomide—Hypotension—Carmustine—brain cancer	0.000124	0.000697	CcSEcCtD
Thalidomide—Hyperhidrosis—Temozolomide—brain cancer	0.000124	0.000697	CcSEcCtD
Thalidomide—Dysgeusia—Etoposide—brain cancer	0.000123	0.000692	CcSEcCtD
Thalidomide—Anorexia—Temozolomide—brain cancer	0.000122	0.000687	CcSEcCtD
Thalidomide—Back pain—Etoposide—brain cancer	0.000122	0.000684	CcSEcCtD
Thalidomide—Hypersensitivity—Hydroxyurea—brain cancer	0.000121	0.00068	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Carmustine—brain cancer	0.000121	0.00068	CcSEcCtD
Thalidomide—Muscle spasms—Etoposide—brain cancer	0.000121	0.00068	CcSEcCtD
Thalidomide—Insomnia—Carmustine—brain cancer	0.00012	0.000675	CcSEcCtD
Thalidomide—Paraesthesia—Carmustine—brain cancer	0.000119	0.00067	CcSEcCtD
Thalidomide—Dyspnoea—Carmustine—brain cancer	0.000118	0.000665	CcSEcCtD
Thalidomide—Somnolence—Carmustine—brain cancer	0.000118	0.000663	CcSEcCtD
Thalidomide—Asthenia—Hydroxyurea—brain cancer	0.000118	0.000662	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000117	0.000657	CcSEcCtD
Thalidomide—Ill-defined disorder—Etoposide—brain cancer	0.000117	0.000656	CcSEcCtD
Thalidomide—Anaemia—Etoposide—brain cancer	0.000116	0.000654	CcSEcCtD
Thalidomide—Insomnia—Temozolomide—brain cancer	0.000116	0.000652	CcSEcCtD
Thalidomide—Decreased appetite—Carmustine—brain cancer	0.000115	0.000649	CcSEcCtD
Thalidomide—Paraesthesia—Temozolomide—brain cancer	0.000115	0.000648	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Carmustine—brain cancer	0.000115	0.000644	CcSEcCtD
Thalidomide—Dyspnoea—Temozolomide—brain cancer	0.000114	0.000643	CcSEcCtD
Thalidomide—Somnolence—Temozolomide—brain cancer	0.000114	0.000641	CcSEcCtD
Thalidomide—Constipation—Carmustine—brain cancer	0.000113	0.000638	CcSEcCtD
Thalidomide—Pain—Carmustine—brain cancer	0.000113	0.000638	CcSEcCtD
Thalidomide—Malaise—Etoposide—brain cancer	0.000113	0.000638	CcSEcCtD
Thalidomide—Vertigo—Etoposide—brain cancer	0.000113	0.000635	CcSEcCtD
Thalidomide—Dyspepsia—Temozolomide—brain cancer	0.000113	0.000635	CcSEcCtD
Thalidomide—Leukopenia—Etoposide—brain cancer	0.000112	0.000633	CcSEcCtD
Thalidomide—Diarrhoea—Hydroxyurea—brain cancer	0.000112	0.000632	CcSEcCtD
Thalidomide—Decreased appetite—Temozolomide—brain cancer	0.000111	0.000627	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Temozolomide—brain cancer	0.000111	0.000623	CcSEcCtD
Thalidomide—Fatigue—Temozolomide—brain cancer	0.000111	0.000622	CcSEcCtD
Thalidomide—Loss of consciousness—Etoposide—brain cancer	0.00011	0.000622	CcSEcCtD
Thalidomide—Cough—Etoposide—brain cancer	0.00011	0.000617	CcSEcCtD
Thalidomide—Pain—Temozolomide—brain cancer	0.00011	0.000617	CcSEcCtD
Thalidomide—Constipation—Temozolomide—brain cancer	0.00011	0.000617	CcSEcCtD
Thalidomide—Feeling abnormal—Carmustine—brain cancer	0.000109	0.000615	CcSEcCtD
Thalidomide—Convulsion—Etoposide—brain cancer	0.000109	0.000613	CcSEcCtD
Thalidomide—Hypertension—Etoposide—brain cancer	0.000108	0.000611	CcSEcCtD
Thalidomide—Dizziness—Hydroxyurea—brain cancer	0.000108	0.000611	CcSEcCtD
Thalidomide—Gastrointestinal pain—Carmustine—brain cancer	0.000108	0.00061	CcSEcCtD
Thalidomide—Chest pain—Etoposide—brain cancer	0.000107	0.000602	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000106	0.000598	CcSEcCtD
Thalidomide—Discomfort—Etoposide—brain cancer	0.000106	0.000595	CcSEcCtD
Thalidomide—Feeling abnormal—Temozolomide—brain cancer	0.000106	0.000594	CcSEcCtD
Thalidomide—Abdominal pain—Carmustine—brain cancer	0.000105	0.00059	CcSEcCtD
Thalidomide—Body temperature increased—Carmustine—brain cancer	0.000105	0.00059	CcSEcCtD
Thalidomide—Gastrointestinal pain—Temozolomide—brain cancer	0.000105	0.00059	CcSEcCtD
Thalidomide—Vomiting—Hydroxyurea—brain cancer	0.000104	0.000587	CcSEcCtD
Thalidomide—Rash—Hydroxyurea—brain cancer	0.000103	0.000582	CcSEcCtD
Thalidomide—Confusional state—Etoposide—brain cancer	0.000103	0.000582	CcSEcCtD
Thalidomide—Dermatitis—Hydroxyurea—brain cancer	0.000103	0.000582	CcSEcCtD
Thalidomide—Headache—Hydroxyurea—brain cancer	0.000103	0.000578	CcSEcCtD
Thalidomide—Infection—Etoposide—brain cancer	0.000102	0.000573	CcSEcCtD
Thalidomide—Urticaria—Temozolomide—brain cancer	0.000102	0.000573	CcSEcCtD
Thalidomide—Abdominal pain—Temozolomide—brain cancer	0.000101	0.00057	CcSEcCtD
Thalidomide—Body temperature increased—Temozolomide—brain cancer	0.000101	0.00057	CcSEcCtD
Thalidomide—Thrombocytopenia—Etoposide—brain cancer	0.0001	0.000565	CcSEcCtD
Thalidomide—Tachycardia—Etoposide—brain cancer	0.0001	0.000563	CcSEcCtD
Thalidomide—Skin disorder—Etoposide—brain cancer	9.96e-05	0.000561	CcSEcCtD
Thalidomide—Hyperhidrosis—Etoposide—brain cancer	9.92e-05	0.000558	CcSEcCtD
Thalidomide—Anorexia—Etoposide—brain cancer	9.78e-05	0.00055	CcSEcCtD
Thalidomide—Hypersensitivity—Carmustine—brain cancer	9.77e-05	0.00055	CcSEcCtD
Thalidomide—Nausea—Hydroxyurea—brain cancer	9.75e-05	0.000548	CcSEcCtD
Thalidomide—Hypotension—Etoposide—brain cancer	9.58e-05	0.000539	CcSEcCtD
Thalidomide—Asthenia—Carmustine—brain cancer	9.52e-05	0.000535	CcSEcCtD
Thalidomide—Hypersensitivity—Temozolomide—brain cancer	9.44e-05	0.000531	CcSEcCtD
Thalidomide—Paraesthesia—Etoposide—brain cancer	9.21e-05	0.000518	CcSEcCtD
Thalidomide—Asthenia—Temozolomide—brain cancer	9.2e-05	0.000517	CcSEcCtD
Thalidomide—Dyspnoea—Etoposide—brain cancer	9.14e-05	0.000515	CcSEcCtD
Thalidomide—Somnolence—Etoposide—brain cancer	9.12e-05	0.000513	CcSEcCtD
Thalidomide—Diarrhoea—Carmustine—brain cancer	9.07e-05	0.000511	CcSEcCtD
Thalidomide—Pruritus—Temozolomide—brain cancer	9.07e-05	0.00051	CcSEcCtD
Thalidomide—Decreased appetite—Etoposide—brain cancer	8.92e-05	0.000502	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Etoposide—brain cancer	8.85e-05	0.000498	CcSEcCtD
Thalidomide—Fatigue—Etoposide—brain cancer	8.84e-05	0.000498	CcSEcCtD
Thalidomide—Dizziness—Carmustine—brain cancer	8.77e-05	0.000494	CcSEcCtD
Thalidomide—Pain—Etoposide—brain cancer	8.77e-05	0.000494	CcSEcCtD
Thalidomide—Constipation—Etoposide—brain cancer	8.77e-05	0.000494	CcSEcCtD
Thalidomide—Diarrhoea—Temozolomide—brain cancer	8.77e-05	0.000493	CcSEcCtD
Thalidomide—Dizziness—Temozolomide—brain cancer	8.48e-05	0.000477	CcSEcCtD
Thalidomide—Feeling abnormal—Etoposide—brain cancer	8.45e-05	0.000476	CcSEcCtD
Thalidomide—Vomiting—Carmustine—brain cancer	8.43e-05	0.000475	CcSEcCtD
Thalidomide—Gastrointestinal pain—Etoposide—brain cancer	8.39e-05	0.000472	CcSEcCtD
Thalidomide—Rash—Carmustine—brain cancer	8.36e-05	0.000471	CcSEcCtD
Thalidomide—Dermatitis—Carmustine—brain cancer	8.36e-05	0.00047	CcSEcCtD
Thalidomide—Headache—Carmustine—brain cancer	8.31e-05	0.000468	CcSEcCtD
Thalidomide—Vomiting—Temozolomide—brain cancer	8.15e-05	0.000459	CcSEcCtD
Thalidomide—Urticaria—Etoposide—brain cancer	8.15e-05	0.000458	CcSEcCtD
Thalidomide—Abdominal pain—Etoposide—brain cancer	8.11e-05	0.000456	CcSEcCtD
Thalidomide—Body temperature increased—Etoposide—brain cancer	8.11e-05	0.000456	CcSEcCtD
Thalidomide—Rash—Temozolomide—brain cancer	8.08e-05	0.000455	CcSEcCtD
Thalidomide—Dermatitis—Temozolomide—brain cancer	8.07e-05	0.000454	CcSEcCtD
Thalidomide—Headache—Temozolomide—brain cancer	8.03e-05	0.000452	CcSEcCtD
Thalidomide—Nausea—Carmustine—brain cancer	7.88e-05	0.000443	CcSEcCtD
Thalidomide—Nausea—Temozolomide—brain cancer	7.61e-05	0.000428	CcSEcCtD
Thalidomide—Hypersensitivity—Etoposide—brain cancer	7.56e-05	0.000425	CcSEcCtD
Thalidomide—Asthenia—Etoposide—brain cancer	7.36e-05	0.000414	CcSEcCtD
Thalidomide—Pruritus—Etoposide—brain cancer	7.26e-05	0.000408	CcSEcCtD
Thalidomide—Diarrhoea—Etoposide—brain cancer	7.02e-05	0.000395	CcSEcCtD
Thalidomide—Dizziness—Etoposide—brain cancer	6.78e-05	0.000382	CcSEcCtD
Thalidomide—Vomiting—Etoposide—brain cancer	6.52e-05	0.000367	CcSEcCtD
Thalidomide—Rash—Etoposide—brain cancer	6.47e-05	0.000364	CcSEcCtD
Thalidomide—Dermatitis—Etoposide—brain cancer	6.46e-05	0.000364	CcSEcCtD
Thalidomide—Headache—Etoposide—brain cancer	6.43e-05	0.000362	CcSEcCtD
Thalidomide—Nausea—Etoposide—brain cancer	6.09e-05	0.000343	CcSEcCtD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—EGFR—brain cancer	4.11e-05	0.000336	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	4.11e-05	0.000336	CbGpPWpGaD
Thalidomide—FGFR2—Disease—DLL1—brain cancer	4.1e-05	0.000335	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	4.09e-05	0.000334	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	4.08e-05	0.000333	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—EGFR—brain cancer	4.08e-05	0.000333	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—RELA—brain cancer	4.07e-05	0.000333	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—brain cancer	4.06e-05	0.000332	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—ERBB2—brain cancer	4.04e-05	0.00033	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—EGFR—brain cancer	4.04e-05	0.00033	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PDGFRA—brain cancer	4.04e-05	0.00033	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—EGFR—brain cancer	4.02e-05	0.000329	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—EGFR—brain cancer	4.01e-05	0.000328	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—STAT3—brain cancer	4.01e-05	0.000328	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	3.96e-05	0.000324	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL2—brain cancer	3.93e-05	0.000321	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	3.92e-05	0.000321	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ABR—brain cancer	3.91e-05	0.00032	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PDGFRA—brain cancer	3.88e-05	0.000317	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TP53—brain cancer	3.84e-05	0.000314	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PDGFRA—brain cancer	3.83e-05	0.000313	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—EGFR—brain cancer	3.81e-05	0.000311	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—brain cancer	3.8e-05	0.00031	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	3.8e-05	0.00031	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—MYC—brain cancer	3.79e-05	0.00031	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GLI2—brain cancer	3.78e-05	0.000309	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	3.78e-05	0.000309	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SKP2—brain cancer	3.77e-05	0.000308	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CDK4—brain cancer	3.77e-05	0.000308	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ABR—brain cancer	3.71e-05	0.000304	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL2—brain cancer	3.7e-05	0.000302	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PDGFRA—brain cancer	3.68e-05	0.000301	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HES1—brain cancer	3.66e-05	0.000299	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	3.65e-05	0.000298	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—EGFR—brain cancer	3.64e-05	0.000298	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—CCND1—brain cancer	3.6e-05	0.000294	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GLI2—brain cancer	3.59e-05	0.000293	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SKP2—brain cancer	3.58e-05	0.000292	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—brain cancer	3.57e-05	0.000292	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GLI1—brain cancer	3.55e-05	0.00029	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IRS2—brain cancer	3.54e-05	0.00029	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—MYC—brain cancer	3.52e-05	0.000288	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—VEGFA—brain cancer	3.5e-05	0.000286	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—brain cancer	3.5e-05	0.000286	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ENO2—brain cancer	3.48e-05	0.000285	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SHH—brain cancer	3.48e-05	0.000285	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	3.47e-05	0.000284	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—STAT3—brain cancer	3.47e-05	0.000283	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	3.45e-05	0.000282	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—EGFR—brain cancer	3.44e-05	0.000282	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	3.43e-05	0.00028	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—IRS2—brain cancer	3.4e-05	0.000278	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	3.4e-05	0.000278	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	3.4e-05	0.000278	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GLI1—brain cancer	3.37e-05	0.000276	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SUFU—brain cancer	3.37e-05	0.000275	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IRS2—brain cancer	3.36e-05	0.000275	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—STAT3—brain cancer	3.31e-05	0.00027	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GFAP—brain cancer	3.25e-05	0.000266	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HES5—brain cancer	3.25e-05	0.000266	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—STAT3—brain cancer	3.25e-05	0.000266	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—IRS2—brain cancer	3.23e-05	0.000264	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SUFU—brain cancer	3.2e-05	0.000261	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.18e-05	0.00026	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	3.18e-05	0.00026	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP2C9—brain cancer	3.16e-05	0.000258	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	3.11e-05	0.000254	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—brain cancer	3.08e-05	0.000252	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GFAP—brain cancer	3.08e-05	0.000252	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—STAT3—brain cancer	3.08e-05	0.000252	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HEY1—brain cancer	3.08e-05	0.000252	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DLL1—brain cancer	3.02e-05	0.000247	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.99e-05	0.000244	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—EGFR—brain cancer	2.95e-05	0.000241	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HEY1—brain cancer	2.92e-05	0.000239	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—brain cancer	2.89e-05	0.000236	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MYC—brain cancer	2.89e-05	0.000236	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—VAV1—brain cancer	2.87e-05	0.000235	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CDK4—brain cancer	2.87e-05	0.000234	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DLL1—brain cancer	2.87e-05	0.000234	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—EGFR—brain cancer	2.83e-05	0.000231	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—EGFR—brain cancer	2.8e-05	0.000229	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	2.77e-05	0.000227	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—RELA—brain cancer	2.77e-05	0.000226	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—ERBB2—brain cancer	2.75e-05	0.000225	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—VAV1—brain cancer	2.72e-05	0.000223	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.72e-05	0.000223	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—BSG—brain cancer	2.68e-05	0.000219	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—brain cancer	2.64e-05	0.000216	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	2.61e-05	0.000213	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SHH—brain cancer	2.57e-05	0.00021	CbGpPWpGaD
Thalidomide—FGFR2—Disease—VAV1—brain cancer	2.52e-05	0.000206	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP2C9—brain cancer	2.51e-05	0.000205	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TRPC6—brain cancer	2.48e-05	0.000203	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	2.45e-05	0.0002	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—RELA—brain cancer	2.45e-05	0.0002	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SHH—brain cancer	2.44e-05	0.000199	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTCH1—brain cancer	2.44e-05	0.000199	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SMO—brain cancer	2.44e-05	0.000199	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ERBB2—brain cancer	2.43e-05	0.000199	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	2.43e-05	0.000198	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CTNNB1—brain cancer	2.41e-05	0.000197	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—brain cancer	2.37e-05	0.000194	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP2C9—brain cancer	2.36e-05	0.000193	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2C9—brain cancer	2.35e-05	0.000192	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PDGFRA—brain cancer	2.35e-05	0.000192	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TRPC6—brain cancer	2.35e-05	0.000192	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—RELA—brain cancer	2.35e-05	0.000192	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ERBB2—brain cancer	2.33e-05	0.000191	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.33e-05	0.00019	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—RELA—brain cancer	2.32e-05	0.00019	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SMO—brain cancer	2.31e-05	0.000189	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTCH1—brain cancer	2.31e-05	0.000189	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—IDH1—brain cancer	2.31e-05	0.000189	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ERBB2—brain cancer	2.31e-05	0.000188	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PDGFRA—brain cancer	2.23e-05	0.000182	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—RELA—brain cancer	2.23e-05	0.000182	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2C9—brain cancer	2.22e-05	0.000182	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ERBB2—brain cancer	2.21e-05	0.000181	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IDH1—brain cancer	2.19e-05	0.000179	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HES1—brain cancer	2.16e-05	0.000177	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	2.14e-05	0.000175	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—BSG—brain cancer	2.13e-05	0.000174	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CTNNB1—brain cancer	2.13e-05	0.000174	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—brain cancer	2.12e-05	0.000173	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—RELA—brain cancer	2.11e-05	0.000172	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—STAT3—brain cancer	2.1e-05	0.000172	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ERBB2—brain cancer	2.1e-05	0.000171	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HEY1—brain cancer	2.07e-05	0.000169	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IRS2—brain cancer	2.06e-05	0.000169	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PDGFRA—brain cancer	2.06e-05	0.000168	CbGpPWpGaD
Thalidomide—PTGS2—Disease—DLL1—brain cancer	2.03e-05	0.000166	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CTNNB1—brain cancer	2.02e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—BSG—brain cancer	2.01e-05	0.000164	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—BSG—brain cancer	2e-05	0.000164	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	1.97e-05	0.000161	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IRS2—brain cancer	1.96e-05	0.00016	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOTCH2—brain cancer	1.95e-05	0.000159	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	1.92e-05	0.000157	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—brain cancer	1.91e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—BSG—brain cancer	1.89e-05	0.000155	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.88e-05	0.000154	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VAV1—brain cancer	1.86e-05	0.000152	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOTCH2—brain cancer	1.85e-05	0.000151	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CTNNB1—brain cancer	1.83e-05	0.00015	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—IDH1—brain cancer	1.83e-05	0.00015	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ENO2—brain cancer	1.82e-05	0.000149	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2C9—brain cancer	1.82e-05	0.000149	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IRS2—brain cancer	1.81e-05	0.000148	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VAV1—brain cancer	1.76e-05	0.000144	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SHH—brain cancer	1.73e-05	0.000141	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ENO2—brain cancer	1.73e-05	0.000141	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—IDH1—brain cancer	1.72e-05	0.000141	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—IDH1—brain cancer	1.72e-05	0.000141	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—brain cancer	1.68e-05	0.000138	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—IDH1—brain cancer	1.63e-05	0.000133	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—brain cancer	1.62e-05	0.000132	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—brain cancer	1.62e-05	0.000132	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	1.61e-05	0.000132	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—STAT3—brain cancer	1.6e-05	0.000131	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—brain cancer	1.6e-05	0.000131	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APC—brain cancer	1.6e-05	0.000131	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HES1—brain cancer	1.6e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—BSG—brain cancer	1.55e-05	0.000126	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—brain cancer	1.54e-05	0.000125	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PDGFRA—brain cancer	1.52e-05	0.000124	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HES1—brain cancer	1.52e-05	0.000124	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.49e-05	0.000122	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SPP1—brain cancer	1.48e-05	0.000121	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—brain cancer	1.45e-05	0.000119	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ENO2—brain cancer	1.45e-05	0.000118	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PDGFRA—brain cancer	1.44e-05	0.000118	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—RELA—brain cancer	1.42e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2C9—brain cancer	1.42e-05	0.000116	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB2—brain cancer	1.42e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—BSG—brain cancer	1.41e-05	0.000115	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SPP1—brain cancer	1.4e-05	0.000114	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ENO2—brain cancer	1.36e-05	0.000111	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ENO2—brain cancer	1.36e-05	0.000111	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—RELA—brain cancer	1.35e-05	0.00011	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB2—brain cancer	1.34e-05	0.00011	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IRS2—brain cancer	1.33e-05	0.000109	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—IDH1—brain cancer	1.33e-05	0.000109	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.32e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ENO2—brain cancer	1.29e-05	0.000105	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—brain cancer	1.28e-05	0.000105	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IRS2—brain cancer	1.27e-05	0.000104	CbGpPWpGaD
Thalidomide—PTGS2—Disease—VAV1—brain cancer	1.25e-05	0.000102	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB2—brain cancer	1.24e-05	0.000101	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTNNB1—brain cancer	1.24e-05	0.000101	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—brain cancer	1.22e-05	9.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—IDH1—brain cancer	1.21e-05	9.91e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—BSG—brain cancer	1.21e-05	9.85e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CG—brain cancer	1.18e-05	9.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APC—brain cancer	1.18e-05	9.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTNNB1—brain cancer	1.18e-05	9.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CG—brain cancer	1.12e-05	9.14e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APC—brain cancer	1.12e-05	9.14e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CTNNB1—brain cancer	1.09e-05	8.87e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.08e-05	8.85e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—STAT3—brain cancer	1.08e-05	8.82e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HES1—brain cancer	1.07e-05	8.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO2—brain cancer	1.05e-05	8.6e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—IDH1—brain cancer	1.04e-05	8.47e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—brain cancer	1.02e-05	8.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PDGFRA—brain cancer	1.02e-05	8.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	9.88e-06	8.07e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—brain cancer	9.81e-06	8.02e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ENO2—brain cancer	9.59e-06	7.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—brain cancer	9.46e-06	7.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—brain cancer	9.31e-06	7.61e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RELA—brain cancer	9.21e-06	7.53e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—brain cancer	9.15e-06	7.48e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IRS2—brain cancer	8.98e-06	7.34e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—brain cancer	8.79e-06	7.18e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RELA—brain cancer	8.74e-06	7.14e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—brain cancer	8.69e-06	7.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—brain cancer	8.6e-06	7.03e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	8.44e-06	6.9e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CG—brain cancer	8.37e-06	6.84e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—brain cancer	8.3e-06	6.78e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO2—brain cancer	8.2e-06	6.7e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—brain cancer	8.09e-06	6.61e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—brain cancer	8.01e-06	6.54e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APC—brain cancer	7.93e-06	6.48e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—brain cancer	7.87e-06	6.43e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—brain cancer	7.67e-06	6.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—brain cancer	7.6e-06	6.21e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—brain cancer	7.05e-06	5.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—brain cancer	6.98e-06	5.71e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—brain cancer	6.69e-06	5.47e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CG—brain cancer	6.64e-06	5.43e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—brain cancer	6.62e-06	5.41e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—brain cancer	6.49e-06	5.3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—brain cancer	6.35e-06	5.19e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CG—brain cancer	6.25e-06	5.11e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CG—brain cancer	6.24e-06	5.1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—brain cancer	6.16e-06	5.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—brain cancer	6.16e-06	5.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—brain cancer	6.02e-06	4.92e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CG—brain cancer	5.9e-06	4.82e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—brain cancer	5.39e-06	4.4e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—brain cancer	5.33e-06	4.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—brain cancer	5.05e-06	4.13e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CG—brain cancer	4.82e-06	3.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—brain cancer	4.7e-06	3.84e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CG—brain cancer	4.4e-06	3.6e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—brain cancer	4.37e-06	3.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—brain cancer	4.27e-06	3.49e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CG—brain cancer	3.76e-06	3.07e-05	CbGpPWpGaD
